CHRS

Coherus Oncology
$1.46
+$0.05 (+3.55%)Jul 27, 2026
2.8FairMoatMint rating

MoatMint rates Coherus Oncology (CHRS) 2.8 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 2.8 out of 10.

Key metrics

The numbers that frame CHRS today
Market cap
$225.20M
P/E (TTM)
1.2
EV / FCF
-0.9
Gross margin
68.1%
EV / Sales
3.2
ROIC
9,214.6%
Div yield
0%
Debt / equity
0.5
52wk Low
$0.81
52wk High
$2.62

CHRS stock rating

How CHRS scores on quality, value, growth, momentum and financial health
2.8out of 10
Fair overallNeutral business, full priceTop 72% of ~5,000 US stocks
QualityFair2.8/10
GrowthNeutral4.6/10
MomentumNeutral4.4/10
ValueNeutral4.9/10
Financial HealthFair3.3/10

Growth

Revenue and earnings trend for CHRS
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about CHRS
Is Coherus Oncology a good buy?
No. Coherus Oncology has poor quality and weak momentum. Both signals point to a weaker setup. Growth looks mixed. The support signal is useful, but not decisive. We think Coherus Oncology is selling at a fair price.
What is the market capitalization of CHRS?
Coherus Oncology's market capitalization is $225.20M.
What is the P/E ratio for CHRS stock?
Coherus Oncology's current P/E ratio is 1.2.
What is the 52-week high for CHRS stock?
The 52-week high for Coherus Oncology is $2.62. The current close of $1.46 is 44.2% below that high.
What is the 52-week low for CHRS stock?
The 52-week low for Coherus Oncology is $0.81. The current close of $1.46 is 80.2% above that low.
Does CHRS stock pay dividends?
Coherus Oncology does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for CHRS?
Coherus Oncology's Debt / Equity ratio is 0.49.